Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Revenue | 12.2B | 2.8% |
Gross Profit | 4.53B | 10.7% |
Cost of Revenue | 7.67B | 1.3% |
Operating expense | 7.37B | 2.2% |
Net Income | 1.68B | 114.1% |
EBITDA | -438M | 95% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 94.6B | 4.4% |
Total Liabilities | 77.6B | 5.9% |
Total Equity | 17B | 3.2% |
Shares Outstanding | 2.03B | 0.2% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | 2.33B | 17.9% |
Cash from investing | -1.32B | 93.3% |
Cash from financing | -4.02B | 127.5% |
EPS
Financial Highlights for Bristol-Myers Squibb in Q2 '24
Bristol-Myers Squibb reported a revenue of 12.2B, which is a 2.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 4.53B, marking a 10.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 7.67B, a -1.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 7.37B, showing a -2.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 1.68B, showing a 114.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -438M, showing a 95% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Bristol-Myers Squibb with growth in revenue, gross profit, and net income.